×
  • Home
  • Research
  • Diagnosis & Therapy
  • Treatment
  • Patient Journey
  • Similar Disorders
  • About CIDP Journey
☰
CIDP Journey
CIDP Journey
Scope of CIDP could be broadened to ‘syndrome’ status

Scope of CIDP could be broadened to ‘syndrome’ status

by Katrina Carr | Apr 23, 2020 | Diagnosis & Therapy

As experts revise the guideline on management of chronic inflammatory demyelinating polyneuropathy, some in the clinical neurology field are calling for a regrouping of CIDP under a more general, overarching term, “CIDP syndrome” (CIDPS). This would include four...
Real-world data back electrodiagnostic testing for suspected peripheral neuropathies

Real-world data back electrodiagnostic testing for suspected peripheral neuropathies

by Katrina Carr | Apr 7, 2020 | Diagnosis & Therapy

style="width: 100%; margin: auto; display: block;" class="vidyard-player-embed" src="https://play.vidyard.com/Z1RiqTHz7RGfP3P7Nfbb4U.jpg" data-uuid="Z1RiqTHz7RGfP3P7Nfbb4U" data-v="4" data-type="inline"/ Electrodiagnostic testing frequently provides important...
Immunoglobulin shortages may be an ordeal for patients with CIDP

Immunoglobulin shortages may be an ordeal for patients with CIDP

by Katrina Carr | Mar 13, 2020 | Treatment

After receiving intravenous immunoglobulin (IVIg) to treat chronic inflammatory demyelinating polyneuropathy (CIDP) for nearly 20 years, Christina Caron heard about a recent immunoglobulin shortage via social media. Then, an outpatient center could not guarantee that...
Experts offer tips for accurate CIDP diagnosis

Experts offer tips for accurate CIDP diagnosis

by Katrina Carr | Mar 5, 2020 | Diagnosis & Therapy

For years, academic neuromuscular neurologists have anecdotally observed the overdiagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) in referred patients – and in the past 5 years, experts have documented the phenomenon and attempted to pinpoint...
Rituximab rising as alternative treatment for refractory CIPD

Rituximab rising as alternative treatment for refractory CIPD

by Katrina Carr | Feb 21, 2020 | Treatment

Early intervention is the key to minimizing disability for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), and data from several recent studies support the monoclonal anti-CD20 antibody rituximab as a possible treatment when first-line...
« Older Entries

Continue Reading


Treatment


+

Research


+

Diagnosis & Therapy


+

Patient Journey


+

Similar Disorders


+

Copyright © 2019 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited.The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer and privacy policy.